These investigations revealed that in certain types of breast cancer, in particular in HER2 positive and triple-negative types, increased stromal TILs are associated with a better clinical outcome [27,50,51] or can even predict response to certain treatment regimens [27,50]. The gene discussed is ERBB2; the disease is breast cancer.